RET and medullary thyroid gland carcinoma: Pharmaceutical research is currently focusing on the development of new TKIs targeting alternative pathways and RET-specific inhibitors with potential clinical implications in patients with RET-negative MTC and RET mutation-positive MTC, respectively.